EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials

Eliano P Navarese iD, Paul Gurbel, Udaya Tantry, Giuseppe Talanas, Klaudyna Grzelakowska, Julia Umińska, Young-Hoon Jeong, Kevin Bliden, Safi U Khan, Jacek Kubica, Timothy D Henry, Michael E Farkouh und 1 weitere

PLOS Medicine · 26.03.2026 · 23 (3) · e1004995

DOI: 10.1371/journal.pmed.1004995 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS Medicine, online erschienen am 26.03.2026. Verfasst von Eliano P Navarese und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life and Health Sciences, Link Campus University, Rome, Italy. Hauptthemen laut MEDLINE: Aspirin, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients at high ischemic or bleeding risk after percutaneous coronary intervention (PCI) require protection against thrombotic events with dual antiplatelet therapy (DAPT) while avoiding bleeding. Although guidelines recommend 12-month DAPT after acute coronary syndrome (ACS), recent trials have tested the safety of early aspirin withdrawal with potent P2Y12-inhibitor monotherapy. Methods and findings We performed a meta-analysis of randomized trials (from inception through August 2025) comparing early aspirin withdrawal (≤3 months) with transition to ticagrelor- or prasugrel-monotherapy versus continued DAPT. Co-primary outcomes were myocardial infarction (MI) and clinically relevant bleeding. Prespecified timing analyses stratified the comparison versus DAPT by aspirin timing: immediate (aspirin noninitiation or in-hospital cessation) and early (post-discharge discontinuation within 3 months). Bayesian models quantified risk-stratified probabilities of benefit and harm; trial sequential analysis (TSA) assessed conclusiveness of evidence. Seven trials ( n = 27,743) were included. P2Y12-inhibitor monotherapy reduced bleeding (HR = 0.55, 95% CI [0.42, 0.71]; p < 0.001) without significantly increasing MI overall (HR = 1.11, 95% CI [0.91, 1.35]; p = 0.31), death, stroke, or stent thrombosis. Immediate aspirin noninitiation/cessation increased MI (HR = 1.41, 95% CI [1.01, 1.97]; p = 0.04), whereas early discontinuation did not (HR = 0.97, 95% CI [0.76, 1.24]; p = 0.82). TSA indicated conclusiveness for bleeding benefit and futility for an MI excess. Analyses restricted to ACS confirmed the overall results. Bayesian analyses corroborated these effects and identified risk-aligned timing: in high bleeding risk, ≤1-month aspirin discontinuation yielded a 100% posterior probability of bleeding benefit (NNT = 12) and 70% probability of MI-safety; in high ischemic risk, 3-month aspirin discontinuation yielded 100% probability of bleeding benefit (NNT = 57) and 86% probability of MI-safety. Limitations include aggregate data only and limited precision for the immediate aspirin withdrawal subgroup.

Conclusions

Among high-risk post-PCI patients on ticagrelor/prasugrel, discontinuing aspirin within 3 months reduces bleeding without an ischemic trade-off versus DAPT. Immediate aspirin noninitiation or cessation should be avoided; timing should be individualized to bleeding and ischemic risk. PROSPERO: CRD420251167706.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPlatelet Aggregation InhibitorsPercutaneous Coronary InterventionDual Anti-Platelet TherapyAcute Coronary SyndromeHumansRandomized Controlled Trials as TopicHemorrhageMyocardial InfarctionTreatment InterruptionTime FactorsTicagrelorPurinergic P2Y Receptor Antagonists

Substanzen

AspirinPlatelet Aggregation InhibitorsTicagrelorPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Life and Health Sciences, Link Campus University, Rome, Italy.
  • SIRIO MEDICINE Research Network, Department of Cardiology, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States of America.
  • Clinical Experimental Cardiology, University of Sassari, Sassari, Italy.
  • Department of Cardiology, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Division of Cardiology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.

ORCID-Profile: Eliano P Navarese

Zitieren

APA

Navarese, E. P., Gurbel, P., Tantry, U., Talanas, G., Grzelakowska, K., Umińska, J., Jeong, Y. H., Bliden, K., Khan, S. U., Kubica, J., Henry, T. D., Farkouh, M. E., & Kereiakes, D. J. (2026). Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. PLOS Medicine, 23(3), e1004995. https://doi.org/10.1371/journal.pmed.1004995

Vancouver

Navarese EP, Gurbel P, Tantry U, Talanas G, Grzelakowska K, Umińska J, et al. Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. PLOS Medicine. 2026;23(3):e1004995. doi:10.1371/journal.pmed.1004995

BibTeX
@article{Navarese2026,
  author = {Navarese, Eliano P and Gurbel, Paul and Tantry, Udaya and Talanas, Giuseppe and Grzelakowska, Klaudyna and Umińska, Julia and Jeong, Young-Hoon and Bliden, Kevin and Khan, Safi U and Kubica, Jacek and Henry, Timothy D and Farkouh, Michael E and Kereiakes, Dean J},
  title = {Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {e1004995},
  doi = {10.1371/journal.pmed.1004995}
}
Kostenlos starten →